share_log
Breakings ·  Dec 23, 2024 19:59
Bristol-Myers Squibb Co - Phase 3 Trials Met Primary Endpoint With Significant Acr20 Response
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment